Please assess the completion status of the following clinical trial:

Trial Title: Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male subjects and non-pregnant female subjects aged 2 to 18 years who are about to receive a kidney transplant and will be on post transplant MMF containing immunosuppressive therapy.~* A signed and dated institutional review board (IRB) approved parental/guardian informed consent form and an IRB approved child assent form if applicable.~* Subjects with stable kidney allografts who are on a stable regimen of MMF (with tacrolimus and steroids)~* May have clinically important abnormalities on clinical and /or laboratory evaluations, only as these abnormalities relate to an underlying condition as determined by the principal investigator.~Exclusion Criteria:~* Children receiving cyclosporine therapy that may interact with MPA entero-hepatic recycling.~* Any medical condition(active or chronic) or prior surgery that may interfere with the pharmacokinetics of MMF as determined by the principal investigator.~* Concomitant medication that may interfere with the pharmacokinetics of MMF as determined by the principal investigator.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).